Exelixis Inc at BMO Capital Markets Biopharma Spotlight Series: Oncology (Virtual) Transcript
Good afternoon. I'm Dan Barclay, CEO of BMO Capital Markets, and it's my pleasure to introduce today's Biopharma Spotlight Series. This is the fifth Biopharma Spotlight Series event we hosted this year, each covering a different area of therapeutics or technology, such as targeted protein degradation, AI-enabled drug discovery and innovations in GI. Today, we'll take a deep dive into the broad and important topic of oncology.
We're joined today by some of the most innovative research and development companies across market caps, including Gilead, Amgen, Insight, Exelixis, Candel Therapeutics and Replimune. These companies have some exciting new developments and stories to share with you.
First, Exelixis' CEO, Michael Morrissey, will discuss their targeted therapies and how the company has transformed itself from a drug discovery company into a commercial powerhouse, a feat very few companies have achieved. Candel and Replimune are working on the next generation of oncolytic viruses. Gilead and Insight are focused on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
